popular

TempoStemBank™-iPSC: Human iPSC Stem Cell Lines

Summary

TempoStemBank™-iPSC: human iPSC lines are derived from human dermal/fibroblasts, blood or cord blood, using our proprietary virus-free, nucleic-acids-free, feeder-free, and serum-free reprogramming technology. The cells express canonical biomarkers of iPSCs (e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4); they have been proven to be multipotent and are able to differentiate into ectoderm, endoderm and mesoderm derivative cell types. Please inquire for ready-to-ship low passage iPSCs (Free culture media included!). 


Academic scientists receive a special rate! Check out our new citations!

Human iPSC Lines, anti-human-Oct4, ICC

More Views

  • Human iPSC Lines, anti-human-Sox2, ICC

Details

TempoStemBank™-iPSC: human iPSC lines are derived from human dermal/fibroblasts, blood or cord blood cells, using our proprietary virus-free, nucleic-acids-free, serum-free, and feeder-free technology. The cells express canonical biomarkers of iPSCs (e.g., e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4); they have been proven to be multipotent and are able to differentiate into ectoderm, endoderm and mesoderm derivative cell types such as glial, neurons, osteoblasts, and hepatocytes.

Please email Tempo Support for Ready-to-Ship low passage iPSCs (Free culture media Included!). 

Academic scientists receive a special rate!

Frequently Requested Disease Models for iPSC lines or iPS-derived cell types in the ectoderm, endoderm, and mesenchymal lineages:

  • Frontotemporal Dementia (FTD)
  • Familial Alzheimer's Disease (FAD; early onset; late onset)
  • Parkinson's Disorder (PD)
  • Multiple Sclerosis (MS)
  • Seizure Disorders (e.g., Epilepsy)
  • Motor Neuron Diseases (e.g., ALS, PLS)
  • Duchenne Muscular Dystrophy (DMD)
  • Spinal Muscular Atrophy (SMA Types I-IV)
  • Friedreich's Ataxia
  • Cardiomyopathy (e.g., Fabry Disease, Primary arrhythmias)
  • Muscular Dystrophy with Early Contractures and Cardiomyopathy
  • Emery-Dreifuss Muscular Dystrophy (EDMD)
  • Osteogenesis Imperfecta
  • Tourette Syndrome
  • Ataxia-Telangiectasia
  • Huntington Disease
  • Williams Syndrome
  • Spinocerebellar Ataxia
  • Warfan Syndrome
  • Affective Disorders (e.g., Bipolar Disorder, Depression.)
  • Schizophrenia
  • Sensory Neuropathy
  • Diabetes (Types: Familial, Juvenile Onset, or Maturity Onset)
  • Fragile X Syndrome
  • Angelman's Syndrome
  • Trisomy 21 (Down Syndrome)
  • Turner Syndrome
  • Sickle Cell Anemia (& carriers)
  • Turcot Syndrome
  • Osteoporosis
  • Paget Disease of Bone
  • Rheumatoid arthritis
  • Von Hippel-Lindau Syndrome (VHL)
  • Chronic Kidney Diseases
  • Charcot-Marie-Tooth Disease
  • Cancer iPSCs (e.g., osteosarcoma, ovarian tumors, colorectal, neuroblastoma, glioblastoma multiforme (GBM), renal cell carcinoma (RCC))
  • Ethnically Diverse Donors' Derived iPSCs 
  • Please send inquiry to Tempo Support

Applications:

  • Disease modeling and drug discovery (iPSCs: grown as monolayers vs. colonies)
  • Developmental and lineage differentitation studies
  • High Content Screening (e.g., expression of differentiation markers)
  • Scalable for BioBanking (GMP-grade possible. Please send inquiry to Tempo Support)

Growth Reagents (Suggested):

  • Matrigel hESC-qualified matrix (Corning)
  • 10μM Y-27632 ROCK inhibitor (Sigma)
  • Accutase, for passaging cells (Innovative Cell Technologies)

TempoStemBank™-iPSC Lines and Disease Models

Characterizations performed:

  • biomarkers confirmation (e.g., Oct4, Tra-1-60, Tra-1-81, Sox2, Nanog, and SSEA-4);
  • functional assay (upon request);
  • multi-lineage confirmations (upon request);
  • karyotype testing (upon request);

Technology used: in-house developed proprietary virus-free, nucleic-acids-free, serum-free, and feeder-free technology.

Deliverables: >0.5-6.0x10^6 cells (multiple lines or scale-up possible. Please send inquiry to Tempo Support).  BioSafety Level 2.

SKU1002: Please email Tempo Support for ready-to-ship low passage iPSCs. Academic scientists receive a special rate!

We ship worldwide.

Citations:

1) Enhanced Astrocyte Responses are Driven by a Genetic Risk Allele Associated with Multiple Sclerosis

2) The Genetic Multiple Sclerosis (MS) Risk Variant rs7665090-G Increases Astrocyte Responses and Lymphocyte Recruitment to White Matter Lesions.

3) Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling

 

Additional Information

Product Use TempoStemBank™-iPSC are intended for basic scientific research, drug discovery, and therapeutics development use only. It is not a product for human testing, therapeutics, or diagnostics.